Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
revexepride + proton pump inhibitor
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Revexepride (SSP-002358, SPD-557) is a potent and highly selective 5-HT4 (5-hydroxytryptamine receptor 4) receptor agonist developed by Shire (now Takeda). It was investigated as an add-on therapy to standard proton pump inhibitor (PPI) treatment for patients with gastroesophageal reflux disease (GERD) who continued to experience persistent symptoms, particularly regurgitation, despite acid suppression therapy. The combination aimed to address underlying motility dysfunction by stimulating gastrointestinal motility via the 5-HT4 receptor. While evaluated in Phase 2b clinical trials, revexepride failed to demonstrate superior efficacy over placebo in reducing persistent GERD symptoms and development was subsequently halted.
- Other names
- revexepride + PPIrevexepride + proton pump inhibitor
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)HTR4 (5-Hydroxytryptamine receptor 4)
Beyond the preview
Go deeper on revexepride + proton pump inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on revexepride + proton pump inhibitor.